Business
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. “2024 was a year of significant
About this update from Gain Therapeutics, Inc.
[{"type":"image","alt":"Gain Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Gain Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nsPBXqjXYfLs4XgIgz1iUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699","width":150,"height":72}},"lazy":false},{"type":"text","content":"First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025","length":89,"tagName":"p"},{"type":"text","content":"BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update.","length":379,"tagName":"p"},{"type":"text","content":"“2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson’s disease with or without GBA1 mutation,” said Gene Mack, President and CEO of Gain. “Building upon this momentum in 2025, we have recently initiated dosing in our Phase 1b trial of GT-02287 and look forward to sharing results from a first analysis of the study anticipated for the end of the second quarter of 2025. We believe the observations from this analysis will mark a significant value inflection point for the GT-02287 program and importantly, inform the planning of our Phase 2 study during the second half of 2025. At the same time, we are working towards expanding GT-02287 clinical development to the U.S. and continue to have productive dialogue with the FDA. We look forward to providing continued updates on our progress as we aim to achieve these milestones throughout the year.”","length":1029,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2024 and Recent Corporate Highlights","length":51,"tagName":"p"},{"type":"text","content":"Pipeline Updates","length":16,"tagName":"p"},{"type":"list","it...